Abstract: Disruption of sleep causes adverse health outcomes and poor quality of life. People with sleep disruption have higher levels than people without disrupted sleep of depression and anxiety and increased rates of cardiovascular diseases. Women have a higher incidence than men of insomnia and depression related to poor sleep. The types of complaints differ significantly between the sexes. Women are more likely than men to complain of insomnia, headache, irritability, and fatigue than the ''typical'' symptoms of loud snoring and breathing cessation during sleep. Hormones play an important role in sleep in women. Reproductive hormones were found to have a protective effect on sleep apnea in women of premenopausal age. Pregnancy is another period when the prevalence of sleep apnea and restless leg syndrome increases from hormonal effect. Cardiovascular mortality is high in women with obstructive sleep apnea. Continuous positive airway pressure therapy improves outcomes in most cases of obstructive sleep apnea. The epidemiology, risk factors, diagnostic criteria, and therapies for the three most common sleep disorders (insomnia, obstructive sleep apnea, and restless leg syndrome), along with effects of menopause, pregnancy, and social factors on sleep in women, are key considerations for clinicians caring for female patients across the adult life span.
S
leep is essential for normal physiologic function. Chronic sleep deprivation and poor-quality, fragmented sleep result in excessive daytime sleepiness, neurocognitive dysfunction, memory impairment, depression, anxiety, dysglycemia, systemic inflammation, heart rhythm abnormalities, atherosclerosis, and cardiovascular events. 1 Although the differences in sleep physiology between men and women are modest, the prevalence and presentation of sleep disorders vary considerably between the sexes. Women with obstructive sleep apnea (OSA) are more likely to present with atypical complaints than with the more classical symptoms usually seen in men. 1a,2 Sleep duration also varies with sex and race. Reproductive hormones play important roles in sleep physiology for women at different ages and times of their lives. The epidemiology, risk factors, and treatment of the most common sleep disorders (insomnia, OSA, and restless leg syndrome [RLS] ), complicated by the effects of menopause, pregnancy, and social factors, are essential issues in understanding sleep disorders in women.
Insomnia
Insomnia includes difficulty falling asleep, inability to maintain sleep, and/or early-morning awakening, which negatively affects daytime function. Symptoms should be present for 91 month to diagnose insomnia, which is more common in women than in men. The American Insomnia Survey (7428 respondents) documented a prevalence of 27% in women (vs 19% in men), with substantial associated workplace costs. 2 A range of 10% to 15% of the US population complains of insomnia with resulting impaired daytime function and 30% of the population expresses dissatisfaction with the quality of their sleep. 3 Women are more likely to report sleep disturbances and are 41% more likely than men to experience insomnia.
The reasons for these differences are incompletely understood. Menopause, late-luteal phase of the menstrual cycle, and third trimester of pregnancy are associated with a particularly high prevalence of insomnia, 5 with approximately 50% of perimenopausal woman reporting significant symptoms. 6 Chronic insomnia also is prevalent among cancer patients, especially women with breast cancer. 7 Women also experience higher rates than men of depression, anxiety, and other psychiatric disorders that can contribute to insomnia, and persistent insomnia itself increases fourfold the likelihood of developing major depressive disorder. 4 Sleep restriction was found to cause aberration of the adrenocortical rhythm, increasing the risk of depression among women.
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Sleep restriction also is associated with a 28% increase in the daytime level of the orexigenic hormone ghrelin, contributing to increased appetite and weight gain among patients with insomnia.
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The etiology of insomnia is multifactorial in most women. Insomnia and insomnia-related disorders are classified in the second edition of The International Classification of Sleep Disorders.
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The duration of sleep also varies between the sexes and whites and blacks. In the cohort of the Coronary Artery Risk Development in Young Adults (CARDIA) study, the average sleep duration was 6.7 hours in white women, 6.1 hours in white men, 5.9 hours in black women, and 5.1 hours in black men. Increasing income level was associated with increased sleep efficiency and low socioeconomic status with decreased sleep efficiency and increased sleep latency. 13 Psychological and behavioral interventions are effective and recommended to treat insomnia. The American Academy of Sleep Medicine has developed a practice parameter for these treatments (Table 1). 14 Thirty percent of patients with insomnia have contributory poor sleep hygiene. Good sleep hygiene practices should be prescribed for all patients in addition to other treatments ( Fig. 1 ) because sleep hygiene education alone is ineffective. 15 The current Food and Drug AdministrationYapproved pharmacological treatments for insomnia include benzodiazepine receptor agonists and melatonin receptor agonists. Potential adverse effects of the former include residual sedation, memory and performance impairment, falls, undesired behaviors during sleep, somatic symptoms, and drug interactions. A number of other prescription medications (eg, sedating antidepressants, antiepileptics) also are used off-label, as well as nonprescription drugs (eg, sedating antihistamines) and naturopathic agents (eg, melatonin, valerian) to treat insomnia, although safety and efficacy data are limited. 15 In general, symptom pattern, previous treatment failure, comorbid conditions, adverse effects, and medication costs should be considered before starting a hypnotic regimen. Shortto intermediate-acting benzodiazepine receptor agonists or melatonin receptor agonists can be started initially. Medications can be changed or dosages increased based upon the degree of symptom improvement and adverse effects experienced (Fig. 2) . 15 Because depression and insomnia are present more frequently in women than in men, selective serotonin reuptake inhibitors appear to be uniquely effective in their treatment. 16 Cognitivebehavioral therapy appears to improve insomnia in women with breast cancer 17 ; however, there is no consensus on sex-specific insomnia treatment strategies for women. 16 
OSA
OSA is a common disorder characterized by repetitive upper-airway collapse during sleep. The diagnosis is made by nocturnal polysomnography, which measures the total number of apneic and hypopneic episodes per hour of sleep (the Apnea-Hypopnea Index [AHI]). The American Academy of Sleep Medicine has defined OSA as mild (AHI 5Y15), moderate (AHI 15Y30), or severe (AHI 930) based on the frequency of these events.
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The disorder is associated with conditions that contribute to excess mortality in adults, including cardiovascular disease, stroke, neurocognitive dysfunction, and motor vehicle crashes. 19 The estimated prevalence of OSA is 9% in women (vs 24% in men). 20, 21 The Wisconsin Sleep Cohort Study estimated that sleep apnea was undiagnosed in 990% of women with moderate to severe sleep apnea 21 and suggested that underdiagnosis related to atypical symptomatology may explain much of the perceived disparity. 22 Loud snoring, breathing pauses during sleep, and excessive daytime sleepiness are classic symptoms seen in most men with OSA, whereas atypical symptoms such as insomnia, morning headache, fatigue, tiredness, depression, and anxiety are more common presentations in women. Women are two to three times less likely than men to report classic OSA symptoms, 23 with approximately 20% of women presenting primarily with complaints of insomnia, supporting the position of frequently missed diagnoses. As such, women are more likely to be treated inappropriately for depression, anxiety, or hypothyroidism than are men with the same severity of OSA. 24 In women at risk for OSA, other less typical symptoms, including memory loss, poor concentration, decreased libido, irritability, worsening unexplained fatigue, and tiredness, should be appraised using a comprehensive sleep evaluation. An large neck size (916 in.), a body mass index (BMI) 930 kg/m 2 , and the presence of structural abnormalities (oropharyngeal narrowing, retrognathia, macroglossia, uvula elongation, high arched hard palate, nasal septal deviation) should be sought during physical examination; each anatomic finding increases the probability of OSA. 25 Obesity may be the most important risk factor for OSA. Women with OSA are more likely to be obese than are men with OSA of similar severity. 26 In a study of women with BMI 930 kg/m, 2 one-third of asymptomatic women were found to have OSA by polysomnographic criteria, and a significant correlation was identified between AHI and BMI in this cohort. 27 Hormonal status also contributes to sleep abnormalities in women. A study in a general population evaluated the effects of menopause and hormone therapy (HT) on polysomnographic findings in women and compared the female cohorts to the male cohorts. 28 The study found that women slept objectively better than men and that sleep in young women is more resistant to external stressors. Menopause showed a negative effect on sleep: Postmenopausal women had longer sleep latency, less slow-wave sleep, and less deep sleep as compared with premenopausal subjects. Postmenopausal women not receiving HT had longer sleep latency than did those on treatment, suggesting that estrogens may exert a protective effect on sleep integrity. Bixler et al found a low prevalence of OSA (0.6%) among premenopausal women and postmenopausal women receiving HT (0.5%) compared with postmenopausal women not receiving HT (2.7%). 29 Vasomotor symptoms (VMS), particularly hot flashes, correlate strongly with subjective sleep complaints. 30 Declining estradiol levels during the climacterium demonstrates an association with increased VMS, trouble sleeping, and diminished sexual response. 31 Worse mood associates with poorer sleep and concurrent VMS, explaining in part the increased anxiety, depression, and mental health issues seen in some postmenopausal women. In a prospective crossover study, postmenopausal women with OSA were treated with estrogen alone, and with an estrogen-progestin combination. 32 Polysomnography was performed at baseline and repeated after 3 to 4 weeks of each regimen. Both treatment strategies reduced OSA, with a 50% reduction of AHI following estrogen-progesterone treatment and a 25% reduction following estrogen-only therapy. 32 Estrogen effects were further studied in two groups of postmenopausal women (one receiving HT and the other untreated); treated women had lower free cortisol levels and better polysomnographic sleep parameters than untreated subjects. 33 Despite these data, HT is not a recommended treatment for perimenopausal OSA at this time. 32, 33 Women with established cardiovascular disease experience more coronary and thromboembolic events and greater mortality when prescribed HT, 34 and with the higher incidence of major cardiovascular risk determinants in OSA patients overall, the potential for harm is significant. Further long-term outcomes studies are needed to evaluate the net effect of HT on postmenopausal women with OSA.
Cardiovascular complications associated with untreated OSA include hypertension, myocardial infarction, congestive heart failure, atrial fibrillation, and stroke. 35 Upper airway collapse during sleep results in intrathoracic pressure swings, which cause myocardial transmural pressure gradients, stretching thin atrial walls. Over time, this combined with secondary pulmonary hypertension from hypoxic vasoconstriction may result in atrial enlargement, impaired intraatrial conduction, enhanced atrial automaticity, and subsequent atrial fibrillation. 36, 37 Repetitive intermittent hypoxia from OSA also produces oxidative stress and inflammation (with release of cytokines, interleukins, and tumor necrosis factor) and promotes fibrosis and endothelial dysfunction, which results in pathologic vasoconstriction and an increased incidence of atherosclerosis. 38 In a prospective study of 1116 women for 88 months, the hazard ratio for cardiovascular mortality in patients with untreated severe OSA was 3.50 (95% confidence interval 1.23Y9.98); adequate continuous positive airway pressure (CPAP) therapy reduced the relative risk to 0.55 (95% confidence interval 0.17Y1.74) after controlling for age, BMI, previous cardiovascular history, hypertension, and diabetes. These data strongly suggest that severe OSA independently associates with cardiovascular mortality and that CPAP therapy may reduce cardiovascular death in these patients. 39 Many metabolic conditions also demonstrate an association with OSA. Impaired glucose metabolism, demonstrated by elevated HbA1C concentrations, correlates with increasing AHI among patients with OSA. 40 Diabetics have a high prevalence of OSA, and CPAP improves glucose control in these patients. 41 Women with a history of witnessed OSA have a threefold increased risk of diabetes. 42 Insulin-resistant women with polycystic ovary syndrome are at high risk for OSA, early-onset diabetes, and cardiovascular disease; CPAP treatment improves insulin sensitivity, decreases sympathetic nervous system outflow, and decreases diastolic blood pressure in these patients. 43 Secretion of growth hormone and prolactin are regulated by processes occurring during stage 3 and rapid-eye-movement sleep; when these sleep components are disturbed by OSA, hormone concentrations fall and symptomatic deficiency states develop. 44 Neurocognitive dysfunction, including dementia, memory loss, depression, and anxiety, also can result from untreated OSA. There is a strong association between depression and OSA, although it is unclear whether depression is triggered by sleep deprivation and subsequent sleepiness or whether OSA itself causes this mood disorder. 43 OSA should be approached as a chronic disease requiring long-term, multidisciplinary management. Medical, behavioral, and surgical treatment options are available and patients should be active participants in the treatment decision process. Positive airway pressure therapy (PAP), the treatment of choice for all degrees of OSA, provides pneumatic splinting of the upper airway and is effective in reducing AHI. 48 It may be delivered in CPAP, bilevel PAP, or autotitrating PAP modes. Full-night, provider-observed polysomnography performed in a sleep laboratory is the preferred approach to titrate to optimal PAP parameters. 44 Compliance is a major challenge. Ye 56 found that CPAP improved functional status and OSA symptoms in both sexes, but CPAP compliance was not different between women and men. Nino-Murcia 45 confirmed that CPAP compliance rates (65%Y83%) were similar between the sexes, whereas a population-based prospective study found that female patients used CPAP more frequently than their male counterparts. 46 Behavioral therapy, including sleep hygiene (Fig. 1) , weight reduction, exercise, alcohol avoidance, and bedtime sedatives are important adjuncts to PAP. Oral appliances (mandibular repositioning or tongue retaining devices) may improve upper airway patency. 47 Surgical therapy is site directed and patient based. Nasal (septoplasty, turbinate reduction, nasal polypectomy), oropharyngeal (uvulopalatoplasty, tonsillectomy, adenoidectomy), and global (maxilla-mandibular advancement) airway procedures can be considered based upon patient anatomy in individuals who fail less-invasive treatment. Bariatric surgery may be needed for patients with refractory obesity. 25 To date, most treatment trials have been conducted in male patients and few trials have included enough women to define differences in the efficacy of various modalities in female patients. 48, 49 Selected clinical studies including female patients are presented in Table 2 .
Restless Leg Syndrome
This movement disorder is characterized by an urge to move the legs, typically during rest, which is relieved by activity. Symptoms are often accompanied by sensations of ''creeping,'' ''pulling,'' ''itching,'' or ''tingling,'' and the diagnosis requires the presence of sensory symptoms. 58 The International Restless Leg Syndrome Study Group developed standardized criteria for the diagnosis of RLS (Fig. 3) , 12 which were modified by a consensus conference in 2002 (Fig. 4) . 58 The prevalence ranges from 4% to 29% in the general population 59, 60 and increases with age. Prospective cohort data suggest that 11.7% of women are affected, 61 and overall prevalence is higher among women (13.9%) than men (6.1%) in another cohort analysis. 62 Although 80% of patients with RLS will have nocturnal periodic limb movements, many patients with these abnormal movements do not have RLS. Periodic limb movements are characterized by episodic repetitive, highly stereotyped limb movements that occur during sleep and by resulting clinical sleep disturbances that cannot be explained by another sleep disorder. 10 Although periodic limb movements may be observed during polysomnography in patients with RLS, the diagnosis is made on the basis of clinical symptoms (Fig. 4) and a sleep study is not necessary.
Although the mechanism of this disease is unknown, dopaminergic dysfunction is thought to be an underlying component. 63Y65 The current consensus theory on the pathophysiology of RLS is the ''iron dopamine hypothesis.'' Iron is a cofactor for the enzyme tyrosine hydroxylase, which performs a rate-limiting enzymatic step in the formation of dopamine. Patients with RLS show a greater circadian variation of dopamine metabolites, consistent with the circadian (evening concentrated) symptom clustering in this disorder. 44 In addition to reducing quality of life, RLS may predispose to significant morbidity and excess mortality. A positive correlation between RLS and coronary artery disease was found in a large number of women (n = 70,694) in a prospective study. Women with RLS for Q3 years demonstrated an elevated risk for nonfatal myocardial infarction and fatal coronary heart diseases. 66 Iron-deficiency anemia, pregnancy, smoking, neuropathy, rheumatoid arthritis, multiple sclerosis, diabetes, kidney disease, caffeine and alcohol consumption, and use of H 2 -receptor blockers and some antidepressant medications have been linked to RLS. 44, 63 In a cohort study of women studied during and after pregnancy, 26% were found to have RLS during pregnancy (with symptoms being most common during the third trimester), which tended to disappear after delivery. Affected women had lower hemoglobin concentrations compared with nonaffected women, 67 supporting the theory that iron status may contribute to RLS. 
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The treatment of RLS is multimodal. The American Academy of Sleep Medicine developed recommendations for pharmacotherapy. 45, 68 A treatment algorithm (Fig. 5) describes an organized strategy. 68 Avoidance of certain foods (eg, caffeine, alcohol) and drugs (eg, antihistamines, neuroleptics, some dopamine antagonists) can be helpful. Selective serotonin receptor blockers, tricyclic antidepressants, and lithium may worsen RLS symptoms and also should be avoided whenever possible. 69 RLS often is underdiagnosed. In a large multinational primary care population of 23,052 patients, 68% of women had RLS; however, only 12.9% received the diagnosis, despite 64.8% reporting their RLS symptoms to a physician. Published data on women with RLS are few and more research focusing on the symptoms and treatment options for women is needed to tailor both diagnostic and treatment strategies. 60 
Conclusions
Sleep disorders are far more common in women than previously appreciated and presenting symptoms often differ from those in men. Although insomnia itself is more prevalent among women, it can constitute an atypical presentation of other sleep disorders such as OSA in women. Women often are incorrectly diagnosed as having and been treated for anxiety, depression, chronic fatigue, and psychosomatic disorders when having OSA instead. Postmenopausal women carry a higher risk for OSA and should be screened with a comprehensive sleep evaluation and sleep study if these symptoms are present. Cardiovascular risks of untreated OSA are high and women should be aware of their individual risks. PAP therapy should be offered to women with OSA and other treatment options should be discussed if they fail to improve with optimal PAP therapy. RLS is common among women of all ages, but it is more frequent during pregnancy. Correction of iron deficiency and use of dopaminergic medications can be helpful for treatment.
Sleep is essential for women to live a functional, productive life. Diagnostic evaluations should be performed and, if needed, treatment prescribed when sleep is disturbed.
